1,181 results match your criteria: "Germany M.E.; and Berlin Institute of Health[Affiliation]"
Nat Genet
October 2024
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Autosomal recessive coding variants are well-known causes of rare disorders. We quantified the contribution of these variants to developmental disorders in a large, ancestrally diverse cohort comprising 29,745 trios, of whom 20.4% had genetically inferred non-European ancestries.
View Article and Find Full Text PDFNeurology
October 2024
From the Department of Psychiatry and Neurosciences (X.W., S.D.F., L.-S.S., L.P., O.P.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Experimental and Clinical Research Center (ECRC) (X.W., S.D.F., L.-S.S., L.P., O.P.); German Center for Neurodegenerative Diseases (DZNE) (S.D.F., J.P., E.J.S., S.A., O.P.); Department of Psychiatry and Psychotherapy (J.P., E.J.S., S.A.), Charité, Berlin; Department of Psychiatry and Psychotherapy (J.P.), School of Medicine, Technical University of Munich, Germany; University of Edinburgh and UK DRI (J.P.), United Kingdom; German Center for Neurodegenerative Diseases (DZNE) (A. Schneider, K.F., F.J., A. Spottke, N.R.-K., F.B., M.W., S.W., A. Ramirez, L.K., M.S.), Bonn; Department of Neurodegenerative Disease and Geriatric Psychiatry (A. Schneider, K.F., M.W., S.W., A. Ramirez, L.K., M.S.), University of Bonn Medical Center; German Center for Neurodegenerative Diseases (DZNE) (J.W.), Goettingen; Department of Psychiatry and Psychotherapy (J.W., N.H.), University Medical Center Goettingen, University of Goettingen, Germany; Neurosciences and Signaling Group (J.W.), Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Portugal; Department of Psychiatry (F.J., A. Rostamzadeh), Medical Faculty, University of Cologne; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) (F.J., A. Ramirez), University of Cologne, Köln; German Center for Neurodegenerative Diseases (DZNE) (E.D., W.G., E.I.I.), Magdeburg; Institute of Cognitive Neurology and Dementia Research (IKND) (E.D., E.I.I.), Otto-von-Guericke University, Magdeburg; Department for Psychiatry and Psychotherapy (E.I.I.), University Clinic Magdeburg; German Center for Neurodegenerative Diseases (DZNE) (K.B., M.E., R.P.), Munich; Institute for Stroke and Dementia Research (ISD) (K.B., D.J., M.E.), and Department of Psychiatry and Psychotherapy (R.P., B.-S.R.), University Hospital, LMU Munich; Munich Cluster for Systems Neurology (SyNergy) (R.P.), Germany; Ageing Epidemiology Research Unit (AGE) (R.P.), School of Public Health, Imperial College London; Sheffield Institute for Translational Neuroscience (SITraN) (B.-S.R.), University of Sheffield, United Kingdom; Department of Neuroradiology (B.-S.R.), University Hospital, LMU Munich; German Center for Neurodegenerative Diseases (DZNE) (S.J.T., I.K., D.G.), Rostock; Department of Psychosomatic Medicine (S.J.T., I.K., D.G.), Rostock University Medical Center; German Center for Neurodegenerative Diseases (DZNE) (C.L., M.H.J.M.), Tübingen; Section for Dementia Research (C.L.), Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy (C.L., M.H.J.M.), University of Tübingen; Department of Neurology (A. Spottke), University of Bonn, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (M.T.H.), University of Luxembourg, Belvaux; Division of Neurogenetics and Molecular Psychiatry (A. Ramirez), Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; and Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (A. Ramirez), San Antonio, TX.
Neurology
October 2024
From the Department of Neurology (L.S., F. Akpokiere, D.M.M., K.P., V.D., K.B., T.M.B., N.S.K., F. Khan, C.S., N. Mohammadzadeh, E.D.G., K.F., S. Yaghi), Warren Alpert Medical School of Brown University, Providence, RI; Vancouver Stroke Program (T.S.F., L.Z., P.G.), Division of Neurology, University of British Columbia, Vancouver, Canada; Department of Neurology (C.R.L.G.), Atrium Health, Charlotte, NC; Department of Neurology (J. Muppa, N.H.), University of Massachusetts Chan Medical School, Worcester; Department of Neurology (M. Affan, O.U.H.L.), University of Minnesota, Minneapolis; Department of Neurology (M.R.H., K.A., D.J.S., M. Arnold), Inselspital, University Hospital and University of Bern, Switzerland; Department of Neurology (S.S.O., R. Crandall), University of Colorado, Denver; Department of Neurology (E.L.), Weill Cornell Medicine, New York; ; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez (D.L.-M., A. Arauz), Mexico City, Mexico; Service de neurologie (A.N., M.B., E.T.), Université Caen Normandie, CHU Caen Normandie, France; Department of Neurology (J.A.S., J.S.-F., V.B.), Coimbra University, ; Department of Internal Medicine (P.C.-C., M.T.B.), São João University Hospital, Porto, Portugal; Department of Neurology (M.K., D.M.), Corewell Health, Grand Rapids, MI; Department of Neurology (M.K.), Mayo Clinic, Rochester, MN; Department of Neurology (A.R., O.K.), University of Pennsylvania, Philadelphia; Neurology and Neurorehabilitation (J.E.K., S.T.E., C.T.), University Department of Geriatric Medicine FELIX PLATTER, Department of Clinical Research, University of Basel, and University Hospital Basel, Switzerland; Stroke Center (D.A.d.S.), Centro Hospitalar Universitário Lisboa Central, and Institute of Anatomy, Faculdade de Medicina da Universidade de Lisboa; Department of Neurology (M.D.S.); Department of Neuroradiology (S.B.R.), Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal; Vancouver Stroke Program (S. Mancini), Division of Neurology, University of British Columbia, Vancouver, Canada; Department of Neurology (I.M., R.R.L.), Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Neurology with Experimental Neurology (R.V.R., C.H.N.), Charite Universitätsmedizin-Berlin and Center for Stroke Research, Berlin, and Berlin Institute of Health, Germany; Department of Neurosciences (R. Choi, J. MacDonald), ChristianaCare, Newark, DE; Department of Neurology (R.B.S.), University of California at San Diego; Department of Neurology (X.G.), Loma Linda University, Loma Linda, CA; Department of Neurology (M. Ghannam, M. Almajali, E.A.S.), University of Iowa, Iowa City; Department of Neurosciences (B.R., F.Z.-E., A.P.), Université de Montréal, Canada; Department of Neurology (A.C.F., M.F.B., D.C.), Hospital de Santa Maria, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Portugal; Neurology and Stroke Unit (M. Romoli, G.D.M., M.L.), Department of Neuroscience, Bufalini Hospital, Cesena, Italy; Department of Neurology (Z.K., K.J.G.), Mayo Clinic, Rochester, MN; Department of Neurology (L.K., J.A.F.), NYU Langone Health, New York; Department of Neurology (J.Y.A., J.A.G.), Washington University, Saint Louis, MO; Neurology Unit, Stroke Unit (M. Zedde, I.G.), Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia; Neuroradiology Unit (R.P.), Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia; Department of Internal Medicine (H.N.), Centro Hospital Universitario do Algarve, Faro, Portugal; Department of Neurology (D.S.L., A.M.), University of California at Los Angeles; Department of Neurology (A.C., B.M.G., R.W.), Duke University, Durham, NC; Department of Neurology (W.K.), University of North Carolina Health Rex, Raleigh; Department of Neurology (S.A.K., M. Anadani), Medical University of South Carolina, Charleston, SC; Department of Neurosurgery (K.P.K.), Medical University of South Carolina, Charleston, SC; Department of Neurology (A.E., L.C., R.C.R., Y.N.A., E.A.M.), University of Cincinnati Medical Center, OH; Department of Neurology (E.B., T.L.T.), University of Alabama at Birmingham; Department of Neurology (M.R.-G., M. Requena), University Hospital Vall d'Hebron, Barcelona, Spain; Department of Neurology (F.G.S.V., J.O.G.), University of Oklahoma; Department of Neurology (V.M.), Einstein-Jefferson Healthcare Network, Philadelphia, PA; Department of Neurology (A.H.), University of Utah, Salt Lake City; Department of Neurology (A.H.); Department of Neurology (S. Sanchez, A.S.Z., Y.K.C., R.S.), Yale New Haven Hospital, New Haven, CT; Department of Neurology (V.Y.V.), All India Institute of Medical Sciences, New Delhi, India; Department of Neurology (S. Yaddanapudi, L.A., A. Browngoehl), Thomas Jefferson University, Philadelphia, PA; Department of Neurology (T.R., R.D., Z.L.), Wake Forest Medical Center, NC; Department of Neurology (M.P., J.E.S.), Cooper University, Camden, NJ; Department of Neurology (S. Mayer, J.Z.W.), Columbia University Medical Center, New York, NY; Department of Neurology (J.P.M., D.K.), Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Neurology (P.K., T.N.N.), Boston Medical Center, MA; Department of Neurology (S.D.A., Z.S., A. Balabhadra, S.P.), Hartford Hospital, CT; Department of Neurology (T.S.), Hospital Moinhos de Vento; Department of Neurology (S.C.M., G.P.M.), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Neurology (Y.D.K.), Yonsei University, Seoul, South Korea; Department of Neurology (B.K., C.E.), University of Tennessee at Memphis; Department of Neurology (S. Lingam, A.Y.Q.), Kansas University Medical Center, Kansas City; Department of Neurology (S.F., A. Alvarado), Western Ontario University, London, Canada; Department of Neurology (F. Khasiyev, G.L.), Saint Louis University, MO; Department of Neurology and Stroke Unit (M.M., V.T.), AOOR Villa Sofia-V. Cervello, Palermo, Italy; First Department of Neurology (A.T., V.T.-P.), National and Kapodistrian University of Athens, Greece; Department of Neurology (M.M.M.-M., V.C.W.), Centro Médico Nacional Siglo XXI IMSS., México City; Department of Neurology (F.I., S.E.E.J.), The Miriam Hospital, Providence, RI; Department of Neurocritical Care (S. Liu, M. Zhou), The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology, Hefei, China; Department of Neurology (M.M.A., F. Ali, M.S.), West Virginia University, WV; Department of Neurology (R.Z.M., T.K.-H.), University of Chicago, IL; Department of Neurology (F.S., J.Z.), Sir Run Run Shaw Hospital of Zhejiang University Medical School, Hangzhou, China; Department of Neurology (D.S., J.S., N. Mongare), Aga Khan University, Nairobi, Kenya; Department of Neurology (A.N.S., R.G., Shayak Sen), Cedars Sinai Medical Center, Los Angeles, CA; Department of Neurology (M. Ghani, M.E.), University of Louisville, KY; and Department of Economics (H.X.), University of California, Santa Barbara.
J Health Popul Nutr
September 2024
Indian Institute of Technology, New Delhi, Delhi, India.
An efficient M&E system in public healthcare is crucial for achieving universal health coverage in low- and middle-income countries, especially when the need for service remains unmet due to the exposure of the population to disaster risks and uncertainties. Current research has conducted exploratory and predictive analyses to estimate the determinants of sustainable M&E solutions for ensuring uninterrupted access during and after disasters. The aim was to estimate the efficiency of reaching a higher M&E production frontier via the Cobb‒Douglas model and stochastic frontier model as the basic theoretical and empirical frameworks.
View Article and Find Full Text PDFNeurology
October 2024
From the Department of Radiology and Nuclear Medicine (L.L., S.I., L.E.C., M.T., A.M.W., F.B.), Amsterdam University Medical Centre, Vrije Universiteit; Amsterdam Neuroscience (L.L., S.I., L.E.C., A.M.W., H.M.), Brain Imaging, Amsterdam, The Netherlands; Department of Neurology and Laboratory of Neuroscience (A.M., F.V., N.T., V.S.), IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Radiology (S.I.), Copenhagen University Hospital Rigshospitalet; Cerebriu A/S (S.I.), Copenhagen, Denmark; Clinical Memory Research Unit (L.E.C.), Department of Clinical Sciences, Lund University, Malmö, Sweden; Department of Advanced Biomedical Sciences (M.T.), University "Federico II," Naples, Italy; Department of Psychiatry and Neurochemistry (K.B., C.H.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburgn; Clinical Neurochemistry Laboratory (K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Neuroradiology Department (C.D.P.), University Hospital of Coventry and Warwickshire (UHCW), Coventry; GE HealthCare (C.F.), Amersham; Dementia Research Centre (N.C.F.), UCL Queen Square Institute of Neurology; UK Dementia Research Institute at University College London (N.C.F.), United Kingdom; Laboratory Alzheimer's Neuroimaging and Epidemiology (G.B.F.), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; University Hospitals and University of Geneva (G.B.F.); CIMC - Centre d'Imagerie Médicale de Cornavin (S.H.), Place de Cornavin 18, Genève, Switzerland; Department of Surgical Sciences (S.H.), Radiology, Uppsala University, Sweden; Department of Radiology (S.H.), Beijing Tiantan Hospital, Capital Medical University, P. R. China; Centro de Investigación y Terapias Avanzadas (P.M.-L.), Neurología, CITA-Alzheimer Foundation, San Sebastián, Spain; Centre for Clinical Brain Sciences (D.M., A.W., J.M.W.), The University of Edinburgh; Department of Psychiatry (J.O.B.), School of Clinical Medicine, CB2 0SP, University of Cambridge, United Kingdom; Department of Nuclear Medicine (P.P.), Toulouse University Hospital; ToNIC (P.P.), Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France; Edinburgh Dementia Prevention (C.R.), Centre for Clinical Brain Sciences, Outpatient Department 2, Western General Hospital, University of Edinburgh Brain Health Scotland (C.R.), Edinburgh, United Kingdom; Alzheimer Center Amsterdam (P.S., B.M.T., P.J.V.), Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc; Amsterdam Neuroscience (P.S., B.M.T., P.J.V.), Neurodegeneration, Amsterdam, The Netherlands; Takeda Pharmaceuticals Ltd. (A.J.S.), Cambridge, MA; Department of Medical Physics and Biomedical Engineering (C.H.S.), Centre for Medical Image Computing (CMIC), University College London (UCL); MRC Unit for Lifelong Health & Ageing at UCL (C.H.S.), University College London; School of Biomedical Engineering and Imaging Sciences (C.H.S.), King's College London, United Kingdom; Department of Pathophysiology and Transplantation (F.V., N.T., V.S.), "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy; Alzheimer Center Limburg (P.J.V.), Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, 6229 GS, Maastricht University, The Netherlands; Division of Neurogeriatrics (P.J.V.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Department of Medicine (A.W.), Imperial College London; IXICO (R.W.), EC1A 9PN, London, United Kingdom; Université de Normandie (G.C.), Unicaen, Inserm, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", institut Blood-and-Brain @ Caen-Normandie, Cyceron, Caen, France; German Center for Neurodegenerative Diseases (DZNE) (M.E.), Munich, Germany; Ghent Institute for Functional and Metabolic Imaging (GIfMI) (H.M.), Ghent University, Belgium; Barcelonaβeta Brain Research Center (BBRC) (J.D.G.), Pasqual Maragall Foundation; CIBER Bioingeniería (J.D.G.), Biomateriales y Nanomedicina (CIBER-BBN), Madrid; IMIM (Hospital del Mar Medical Research Institute) (J.D.G.); Universitat Pompeu Fabra (J.D.G.), Barcelona, Spain; UK Dementia Research Institute Centre at the University of Edinburgh (J.M.W.); and Institutes of Neurology and Healthcare Engineering (F.B.), University College London, United Kingdom.
Background And Objectives: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau), atrophy, and cognition.
View Article and Find Full Text PDFNat Protoc
January 2025
Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Hematoxylin- and eosin-stained whole-slide images (WSIs) are the foundation of diagnosis of cancer. In recent years, development of deep learning-based methods in computational pathology has enabled the prediction of biomarkers directly from WSIs. However, accurately linking tissue phenotype to biomarkers at scale remains a crucial challenge for democratizing complex biomarkers in precision oncology.
View Article and Find Full Text PDFJ Gastrointest Oncol
August 2024
Mainz Biomed Germany GmbH, Mainz, Germany.
Background: Colorectal cancer (CRC) is the third most common form of cancer worldwide in terms of incidence and the second in terms of mortality with 1.9 million new cases and 930,000 deaths reported in 2020. Corresponding numbers in the U.
View Article and Find Full Text PDFEur J Heart Fail
December 2024
ANMCO Research Center - Heart Care Foundation, Florence, Italy.
Aims: We analysed baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry.
Methods And Results: Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62-79], 36% women) or outpatient visit for HF (61%, age 66 [58-75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC-affiliated countries. With AHF, 97% were hospitalized, 2.
N Engl J Med
December 2024
From Guy's Severe Asthma Centre, Guy's and St. Thomas' NHS Foundation Trust, and the School of Immunology and Microbial Sciences, King's College London (David J. Jackson), Barts Health NHS Trust (P.E.P.), and GSK (L.J., N.B., S.S., P.H.), London, and the Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford (I.D.P.) - all in the United Kingdom; National Jewish Health, Denver (M.E.W.); the University of Wisconsin-Madison, Madison (Daniel J. Jackson); the University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati (D.B.); Clinical Research Center, Respiratory Medicine, IKF Pneumologie Mainz, Mainz, and Thoraxklinik Heidelberg, Heidelberg - both in Germany (S.K.); State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Joint International Research Laboratory of Respiratory Health, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (R.C.); Fukushima Medical University, Fukushima, Japan (J.S.); Hospital Vithas Xanit Internacional, Málaga, Spain (G.L.M.); Centrum Medyczne Lucyna Andrzej Dymek, Strzelce Opolskie, Poland (L.D.); and GSK, Collegeville, PA (D.S.).
Background: Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.
Methods: In these phase 3A, randomized, placebo-controlled replicate trials, we evaluated the efficacy and safety of depemokimab in patients with severe asthma and an eosinophilic phenotype characterized by a high eosinophil count (≥300 cells per microliter in the previous 12 months or ≥150 cells per microliter at screening) and a history of exacerbations despite the receipt of medium- or high-dose inhaled glucocorticoids. Patients were randomly assigned in a 2:1 ratio to receive either depemokimab (at a dose of 100 mg subcutaneously) or placebo at weeks 0 and 26, plus standard care.
Neurology
October 2024
From the Cardio-CARE (A.Z.), Medizincampus Davos, Switzerland; Department of Cardiology (A.Z.), and Center for Population Health Innovation (POINT) (A.Z.), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany; School of Mathematics, Statistics and Computer Science (A.Z.), University of KwaZulu-Natal, Pietermaritzburg, South Africa; Department of Public Health and Community Medicine (M.E.), Tufts University School of Medicine, Boston, MA; Department of Epidemiology (V.J.H.), University of Alabama at Birmingham School of Public Health; Department of Neurology (W.T.K.), University of Pittsburgh School of Medicine, PA; Department of Neurology (A.S.), University of Texas Southwestern, Dallas; Department of Neurology (A.L.C.S.), and Department of Biostatistics, Epidemiology, and Informatics (A.L.C.S.), University of Pennsylvania Perelman School of Medicine, Philadelphia; and Department of Neurology (J.G.M.), Georgetown University School of Medicine, Washington, DC.
Circ Res
October 2024
Cardiovascular Medicine and the Robert M. Berne Cardiovascular Research Center (A.H.P., L.M., K.-D.M., Y.Y., J.D.C., M.A.E., E.P., H.D., E.M.-Y., B.E.I., K.W.), University of Virginia School of Medicine, Charlottesville.
Background: Hypertension incidence increases with age and represents one of the most prevalent risk factors for cardiovascular disease. Clonal events in the hematopoietic system resulting from somatic mutations in driver genes are prevalent in elderly individuals who lack overt hematologic disorders. This condition is referred to as age-related clonal hematopoiesis (CH), and it is a newly recognized risk factor for cardiovascular disease.
View Article and Find Full Text PDFHypertension
November 2024
Division of Precision Medicine, Department of Medicine, NYU Langone Health, New York (W.-J.Y., R.A., A.L.S., C.M.F., M.E.G.).
Background: The prevalence of hypertension and uncontrolled hypertension may differ by age and sex.
Methods: We included participants in the Atherosclerosis Risk in Communities study at seven study visits over 33 years (visit 1: 15 636 participants; mean age, 54 years; 55% women), estimating sex differences in prevalence of hypertension (systolic blood pressure ≥130 mm Hg; diastolic blood pressure ≥80 mm Hg; or self-reported antihypertension medication use) and uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) using unadjusted and comorbidity-adjusted models.
Results: The prevalence of hypertension increased with age from 40% (ages, 43-46 years) to 93% (ages, 91-94 years).
Circulation
December 2024
Clinic for Electrophysiology (C.S., M.M., L.B., T.F., M.E.H., V.S., M.D., P.S.), Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany.
Arterioscler Thromb Vasc Biol
November 2024
Department of Vascular and Endovascular Surgery (T.F., A.B., K.J.K., J.M., J.O., E.K., I.K., N.S., W.I., M.U.W., H.S., M.E.), University Hospital Duesseldorf, Heinrich-Heine University, Germany.
Eur J Neurol
December 2024
Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Antibiotics (Basel)
August 2024
Department of Operative Dentistry and Periodontology, Center for Dental Medicine, Medical Center-University of Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany.
Cold atmospheric plasma (CAP) is a promising alternative to antibiotics and chemical substances in dentistry that can reduce the risk of unwanted side effects and bacterial resistance. AmbiJet is a device that can ignite and deliver plasma directly to the site of action for maximum effectiveness. The aim of the study was to investigate its antimicrobial efficacy and the possible development of bacterial resistance.
View Article and Find Full Text PDFNat Med
November 2024
Department of Anesthesiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Invest Ophthalmol Vis Sci
August 2024
Department of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Purpose: In AMD, rod-mediated dark adaptation (RMDA) at 5° eccentricity is slower in eyes with subretinal drusenoid deposits (SDDs) than in eyes without. Here we quantified SDD burden using supervised deep learning for comparison to vision and photoreceptor topography.
Methods: In persons ≥60 years from the Alabama Study on Early Age-Related Macular Degeneration 2, normal, early AMD, and intermediate AMD eyes were classified by the AREDS nine-step system.
J Vasc Surg
February 2025
Vascular Surgery, University of Bologna - DIMEC, Bologna, Italy.
Circ Res
August 2024
University of Warwick, School of Life Sciences, Coventry, United Kingdom (J.B.).
Am J Hum Genet
September 2024
Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. Electronic address:
Radiology
August 2024
From the Department of Radiology (B.O., A.N., H.E., F.B., M.B.), Institute for Evidence in Medicine (C.S., T.B.), Institute of Medical Biometry and Statistics (G.S.), Department of Urology (A.S., C.G.), and Berta-Ottenstein-Programme (A.S), Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands (I.G.S); and Department of Diagnostic and Interventional Radiology, Medical Faculty OWL, University of Bielefeld, Klinikum Lippe, Röntgenstrasse 18, 32756 Detmold, Germany (M.E., M.B.).
Background Prostate MRI for the detection of clinically significant prostate cancer (csPCa) is standardized by the Prostate Imaging Reporting and Data System (PI-RADS), currently in version 2.1. A systematic review and meta-analysis infrastructure with a 12-month update cycle was established to evaluate the diagnostic performance of PI-RADS over time.
View Article and Find Full Text PDFComplement Med Res
October 2024
Charité Competence Center for Traditional and Integrative Medicine (CCCTIM), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Background: A fasting conference and scientific symposium on fasting were held in Berlin in June 2023. Researchers and clinicians from around the world shared new findings, clinical insights, and work in progress during a 3-day program.
Summary: Different fasting regimens, including prolonged, short-term, intermittent fasting, and time-restricted eating were discussed for preventive and therapeutic settings.
BMC Microbiol
August 2024
IGE - Institut de Géosciences de l'Environnement, Grenoble, France.
Background: Subsurface microorganisms contribute to important ecosystem services, yet little is known about how the composition of these communities is affected by small scale heterogeneity such as in preferential flow paths including biopores and fractures. This study aimed to provide a more complete characterization of microbial communities from preferential flow paths and matrix sediments of a clayey till to a depth of 400 cm by using 16S rRNA gene and fungal ITS2 amplicon sequencing of environmental DNA. Moreover, shotgun metagenomics was applied to samples from fractures located 150 cm below ground surface (bgs) to investigate the bacterial genomic adaptations resulting from fluctuating exposure to nutrients, oxygen and water.
View Article and Find Full Text PDFBr J Psychiatry
October 2024
Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Background: Childhood trauma is a major risk factor for chronic depression. It has been suggested that adults with chronic depression who have experienced childhood trauma may require long-term treatment owing to a breakdown of basic trust and related difficulties in developing a productive therapeutic relationship.
Aims: As empirical studies have been preliminary and scarce, we studied the effects of psychoanalytic therapy (PAT) versus cognitive-behavioural therapy (CBT) for chronic depression in adults with a history of childhood trauma.